Your browser doesn't support javascript.
Point Prevalence Estimates of Activity-Limiting Long-Term Symptoms among U.S. Adults ≥1 Month After Reported SARS-CoV-2 Infection, November 1, 2021.
Tenforde, Mark W; Devine, Owen J; Reese, Heather E; Silk, Benjamin J; Iuliano, A Danielle; Threlkel, Ryan; Vu, Quan M; Plumb, Ian D; Cadwell, Betsy L; Rose, Charles; Steele, Molly K; Briggs-Hagen, Melissa; Ayoubkhani, Daniel; Pawelek, Piotr; Nafilyan, Vahé; Saydah, Sharon H; Bertolli, Jeanne.
  • Tenforde MW; CDC COVID-19 Response Team, Atlanta, GA, USA.
  • Devine OJ; Eagle Global Scientific, LLC, Alpharetta, GA, USA.
  • Reese HE; CDC COVID-19 Response Team, Atlanta, GA, USA.
  • Silk BJ; CDC COVID-19 Response Team, Atlanta, GA, USA.
  • Iuliano AD; CDC COVID-19 Response Team, Atlanta, GA, USA.
  • Threlkel R; General Dynamics Information Technology, Inc., Atlanta, GA, USA.
  • Vu QM; CDC COVID-19 Response Team, Atlanta, GA, USA.
  • Plumb ID; CDC COVID-19 Response Team, Atlanta, GA, USA.
  • Cadwell BL; CDC COVID-19 Response Team, Atlanta, GA, USA.
  • Rose C; CDC COVID-19 Response Team, Atlanta, GA, USA.
  • Steele MK; CDC COVID-19 Response Team, Atlanta, GA, USA.
  • Briggs-Hagen M; CDC COVID-19 Response Team, Atlanta, GA, USA.
  • Ayoubkhani D; Office for National Statistics, Newport, UK.
  • Pawelek P; Office for National Statistics, Newport, UK.
  • Nafilyan V; Office for National Statistics, Newport, UK.
  • Saydah SH; CDC COVID-19 Response Team, Atlanta, GA, USA.
  • Bertolli J; CDC COVID-19 Response Team, Atlanta, GA, USA.
J Infect Dis ; 2022 Jul 01.
Article in English | MEDLINE | ID: covidwho-1978237
ABSTRACT

BACKGROUND:

Although most adults infected with SARS-CoV-2 fully recover, a proportion have ongoing symptoms, or post-COVID conditions (PCC), after infection. The objective of this analysis was to estimate the number of US adults with activity-limiting PCC on November 1, 2021.

METHODS:

We modeled the prevalence of PCC using reported infections occurring from February 1, 2020 - September 30, 2021, and population-based, household survey data on new activity-limiting symptoms ≥1 month following SARS-CoV-2 infection. From these data sources, we estimated the number and proportion of US adults with activity-limiting PCC on November 1, 2021, as 95% uncertainty intervals, stratified by sex and age. Sensitivity analyses adjusted for under-ascertainment of infections and uncertainty about symptom duration.

RESULTS:

On November 1, 2021, at least 3.0-5.0 million US adults were estimated to have activity-limiting PCC of ≥1 month duration, or 1.2%-1.9% of US adults. Population prevalence was higher in females (1.4%-2.2%) than males. The estimated prevalence after adjusting for under-ascertainment of infections was 1.7%-3.8%.

CONCLUSION:

Millions of US adults were estimated to have activity-limiting PCC. These estimates can support future efforts to address the impact of PCC on the U.S. population.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Diagnostic study / Prevalence study / Risk factors Topics: Long Covid Language: English Year: 2022 Document Type: Article Affiliation country: Infdis

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Diagnostic study / Prevalence study / Risk factors Topics: Long Covid Language: English Year: 2022 Document Type: Article Affiliation country: Infdis